187 related articles for article (PubMed ID: 28916653)
1. YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation.
Huang H; Zhang W; Pan Y; Gao Y; Deng L; Li F; Li F; Ma X; Hou S; Xu J; Li P; Li X; Hu G; Li C; Chen H; Zhang L; Ji H
Cancer Res; 2017 Nov; 77(21):5769-5781. PubMed ID: 28916653
[TBL] [Abstract][Full Text] [Related]
2. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression.
Gao Y; Zhang W; Han X; Li F; Wang X; Wang R; Fang Z; Tong X; Yao S; Li F; Feng Y; Sun Y; Hou Y; Yang Z; Guan K; Chen H; Zhang L; Ji H
Nat Commun; 2014 Aug; 5():4629. PubMed ID: 25115923
[TBL] [Abstract][Full Text] [Related]
3. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
4. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
6. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.
Hsu YL; Hung JY; Chou SH; Huang MS; Tsai MJ; Lin YS; Chiang SY; Ho YW; Wu CY; Kuo PL
Oncogene; 2015 Jul; 34(31):4056-68. PubMed ID: 25381822
[TBL] [Abstract][Full Text] [Related]
7. Repression of YAP by NCTD disrupts NSCLC progression.
Guo J; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Li X; Xi S
Oncotarget; 2017 Jan; 8(2):2307-2319. PubMed ID: 27903989
[TBL] [Abstract][Full Text] [Related]
8. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
9. The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.
Jin D; Guo J; Wang D; Wu Y; Wang X; Gao Y; Shao C; Xu X; Tan S
EBioMedicine; 2018 Nov; 37():188-204. PubMed ID: 30389502
[TBL] [Abstract][Full Text] [Related]
10. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis.
Gill MK; Christova T; Zhang YY; Gregorieff A; Zhang L; Narimatsu M; Song S; Xiong S; Couzens AL; Tong J; Krieger JR; Moran MF; Zlotta AR; van der Kwast TH; Gingras AC; Sicheri F; Wrana JL; Attisano L
Nat Commun; 2018 Aug; 9(1):3510. PubMed ID: 30158528
[TBL] [Abstract][Full Text] [Related]
11. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
[TBL] [Abstract][Full Text] [Related]
12. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Dai XY; Zhuang LH; Wang DD; Zhou TY; Chang LL; Gai RH; Zhu DF; Yang B; Zhu H; He QJ
Oncotarget; 2016 Feb; 7(6):6933-47. PubMed ID: 26771844
[TBL] [Abstract][Full Text] [Related]
13. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.
Hiemer SE; Zhang L; Kartha VK; Packer TS; Almershed M; Noonan V; Kukuruzinska M; Bais MV; Monti S; Varelas X
Mol Cancer Res; 2015 Jun; 13(6):957-68. PubMed ID: 25794680
[TBL] [Abstract][Full Text] [Related]
14. YAP and TAZ are essential for basal and squamous cell carcinoma initiation.
Debaugnies M; Sánchez-Danés A; Rorive S; Raphaël M; Liagre M; Parent MA; Brisebarre A; Salmon I; Blanpain C
EMBO Rep; 2018 Jul; 19(7):. PubMed ID: 29875149
[TBL] [Abstract][Full Text] [Related]
15. YAP Expression and Activity Are Suppressed by S100A7 via p65/NFκB-mediated Repression of ΔNp63.
Li Y; Kong F; Shao Q; Wang R; Hu E; Liu J; Jin C; He D; Xiao X
Mol Cancer Res; 2017 Dec; 15(12):1752-1763. PubMed ID: 28923839
[TBL] [Abstract][Full Text] [Related]
16. Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling.
Wang H; Lu B; Castillo J; Zhang Y; Yang Z; McAllister G; Lindeman A; Reece-Hoyes J; Tallarico J; Russ C; Hoffman G; Xu W; Schirle M; Cong F
J Biol Chem; 2016 Jul; 291(29):15256-66. PubMed ID: 27231341
[TBL] [Abstract][Full Text] [Related]
17. Suppression of YAP by DDP disrupts colon tumor progression.
Li K; Guo J; Wu Y; Jin D; Jiang H; Liu C; Qin C
Oncol Rep; 2018 May; 39(5):2114-2126. PubMed ID: 29512779
[TBL] [Abstract][Full Text] [Related]
18. TEAD4-YAP interaction regulates tumoral growth by controlling cell-cycle arrest at the G1 phase.
Takeuchi S; Kasamatsu A; Yamatoji M; Nakashima D; Endo-Sakamoto Y; Koide N; Takahara T; Shimizu T; Iyoda M; Ogawara K; Shiiba M; Tanzawa H; Uzawa K
Biochem Biophys Res Commun; 2017 Apr; 486(2):385-390. PubMed ID: 28315328
[TBL] [Abstract][Full Text] [Related]
19. 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway.
Ye XY; Luo QQ; Xu YH; Tang NW; Niu XM; Li ZM; Shen SP; Lu S; Chen ZW
J Cell Mol Med; 2015 Mar; 19(3):651-63. PubMed ID: 25712415
[TBL] [Abstract][Full Text] [Related]
20. S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells.
Wang R; Li Y; Hu E; Kong F; Wang J; Liu J; Shao Q; Hao Y; He D; Xiao X
Oncotarget; 2017 Apr; 8(15):24804-24814. PubMed ID: 28177901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
